Biogen Inc. (NASDAQ:BIIB) EVP Adriana Karaboutis sold 380 shares of the business’s stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $313.00, for a total transaction of $118,940.00. Following the completion of the transaction, the executive vice president now owns 7,172 shares in the company, valued at approximately $2,244,836. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Adriana Karaboutis also recently made the following trade(s):
- On Tuesday, October 4th, Adriana Karaboutis sold 262 shares of Biogen stock. The shares were sold at an average price of $311.94, for a total transaction of $81,728.28.
Shares of Biogen Inc. (NASDAQ:BIIB) opened at 305.59 on Monday. The company has a market cap of $66.96 billion, a price-to-earnings ratio of 17.85 and a beta of 0.95. Biogen Inc. has a 12-month low of $223.02 and a 12-month high of $333.65. The company’s 50-day moving average is $308.50 and its 200-day moving average is $279.69.
Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Thursday, July 21st. The biotechnology company reported $5.21 earnings per share for the quarter, beating analysts’ consensus estimates of $4.69 by $0.52. The business earned $2.89 billion during the quarter, compared to analyst estimates of $2.79 billion. Biogen had a net margin of 33.97% and a return on equity of 40.59%. Biogen’s revenue was up 11.7% compared to the same quarter last year. During the same period last year, the business earned $4.22 EPS. Equities research analysts predict that Biogen Inc. will post $20.08 earnings per share for the current year.
Several equities analysts recently issued reports on the stock. Vetr lowered shares of Biogen from a “hold” rating to a “sell” rating and set a $299.76 target price on the stock. in a report on Tuesday, August 2nd. Credit Suisse Group AG reaffirmed a “hold” rating and issued a $322.00 price target on shares of Biogen in a research note on Wednesday, August 3rd. Piper Jaffray Cos. reaffirmed a “neutral” rating on shares of Biogen in a research note on Wednesday, August 3rd. Morgan Stanley reaffirmed a “buy” rating and issued a $385.00 price target on shares of Biogen in a research note on Wednesday, August 3rd. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $319.00 price target on shares of Biogen in a research note on Thursday, August 4th. Ten analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Biogen presently has a consensus rating of “Buy” and an average target price of $347.34.
A number of hedge funds have recently added to or reduced their stakes in BIIB. Howard Hughes Medical Institute purchased a new stake in Biogen during the first quarter worth $135,000. Kings Point Capital Management purchased a new stake in Biogen during the second quarter worth $145,000. Signaturefd LLC raised its stake in Biogen by 217.7% in the second quarter. Signaturefd LLC now owns 718 shares of the biotechnology company’s stock worth $174,000 after buying an additional 492 shares in the last quarter. Lakeview Capital Partners LLC purchased a new stake in Biogen during the second quarter worth $205,000. Finally, BLB&B Advisors LLC purchased a new stake in Biogen during the second quarter worth $206,000. Institutional investors and hedge funds own 86.21% of the company’s stock.
Biogen Inc, formerly Biogen Idec Inc, is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis.
Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.